Browse by author
Lookup NU author(s): Professor Alan Boddy, Emerita Professor Suzanne Cholerton, Professor Ann DalyORCiD, Professor Janice EllisORCiD, Julian Leathart
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The human body is endowed with a large number of xenobiotic chemical metabolizing enzymes, a significant proportion of which are polymorphic and thus render one individual at greater or lesser risk than another of chemically-induced disease. All examples of genetic polymorphism of chemical metabolizing enzymes have been reviewed in relation to their potential to activate and detoxicate procarcinogens and promutagens. Many examples are cited whereby phenotype can act as a carcinogenic risk factor. With the availability of a large amount of DNA sequence data for chemical metabolizing enzymes there has emerged a number of polymerase chain reaction (PCR) strategies aimed at discerning one metabolic phenotype or another. This is seen as a very positive and democratic scientific development, widening the franchise for studies of disease risk. Nevertheless, it is argued that, at these early stages with many laboratory-based scientists scarcely familiar with epidemiological study design, a cautious approach should obtain when interpreting single studies.
Author(s): Idle, J. R., Armstrong, M., Boddy, A. V., Boustead, C., Cholerton, S., Cooper, J., Daly, A. K., Ellis, J., Gregory, W., Hadidi, H., Hofer, C., Holt, J., Leathart, J., McCracken, N., Monkman, S. C., Painter, J. E., Taber, H., Walker, D., Yule, M.
Publication type: Article
Publication status: Published
Journal: Pharmacogenetics
Year: 1992
Volume: 2
Issue: 6
Pages: 246-258
Print publication date: 01/12/1992
ISSN (print): 0960-314X
ISSN (electronic):
URL: http://dx.doi.org/10.1097/00008571-199212000-00002
DOI: 10.1097/00008571-199212000-00002
Notes: Original format: conference proceeding.
Altmetrics provided by Altmetric
